Vistagen Therapeutics Inc (VTGN) is now in the Undervalued zone, suggesting that its current forward PS ratio of 59.46 is considered Undervalued compared with the five-year average of -3.43. The fair price of Vistagen Therapeutics Inc (VTGN) is between 1.47 to 3.03 according to relative valuation method. Compared to the current price of 0.60 USD , Vistagen Therapeutics Inc By Undervalued By 59.36%.

Relative Value

Fair Zone

1.47-3.03

Current Price：0.60

59.36%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Vistagen Therapeutics Inc (VTGN) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Vistagen Therapeutics Inc (VTGN) has a current Price-to-Book (P/B) ratio of 0.40. Compared to its 3-year average P/B ratio of 1.61, the current P/B ratio is approximately -75.25% higher. Relative to its 5-year average P/B ratio of 2.45, the current P/B ratio is about -83.74% higher. Vistagen Therapeutics Inc (VTGN) has a Forward Free Cash Flow (FCF) yield of approximately -198.23%. Compared to its 3-year average FCF yield of -71.79%, the current FCF yield is approximately 176.12% lower. Relative to its 5-year average FCF yield of -68.49%, the current FCF yield is about 189.41% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for VTGN competitors is 21.34, providing a benchmark for relative valuation. Vistagen Therapeutics Inc Corp (VTGN.O) exhibits a P/S ratio of 59.46, which is 178.66% above the industry average. Given its robust revenue growth of 29.49%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of VTGN increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of VTGN in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is VTGN currently overvalued or undervalued?

Vistagen Therapeutics Inc (VTGN) is now in the Undervalued zone, suggesting that its current forward PS ratio of 59.46 is considered Undervalued compared with the five-year average of -3.43. The fair price of Vistagen Therapeutics Inc (VTGN) is between 1.47 to 3.03 according to relative valuation method. Compared to the current price of 0.60 USD, Vistagen Therapeutics Inc is Undervalued By 59.36%.

What is Vistagen Therapeutics Inc (VTGN) fair value?

VTGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Vistagen Therapeutics Inc (VTGN) is between 1.47 to 3.03 according to relative valuation method.

How does VTGN's valuation metrics compare to the industry average?

The average P/S ratio for VTGN's competitors is 21.34, providing a benchmark for relative valuation. Vistagen Therapeutics Inc Corp (VTGN) exhibits a P/S ratio of 59.46, which is 178.66% above the industry average. Given its robust revenue growth of 29.49%, this premium appears sustainable.

What is the current P/B ratio for Vistagen Therapeutics Inc (VTGN) as of Mar 03 2026?

As of Mar 03 2026, Vistagen Therapeutics Inc (VTGN) has a P/B ratio of 0.40. This indicates that the market values VTGN at 0.40 times its book value.

What is the current FCF Yield for Vistagen Therapeutics Inc (VTGN) as of Mar 03 2026?

As of Mar 03 2026, Vistagen Therapeutics Inc (VTGN) has a FCF Yield of -198.23%. This means that for every dollar of Vistagen Therapeutics Inc's market capitalization, the company generates -198.23 cents in free cash flow.

What is the current Forward P/E ratio for Vistagen Therapeutics Inc (VTGN) as of Mar 03 2026?

As of Mar 03 2026, Vistagen Therapeutics Inc (VTGN) has a Forward P/E ratio of -0.46. This means the market is willing to pay $-0.46 for every dollar of Vistagen Therapeutics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Vistagen Therapeutics Inc (VTGN) as of Mar 03 2026?

As of Mar 03 2026, Vistagen Therapeutics Inc (VTGN) has a Forward P/S ratio of 59.46. This means the market is valuing VTGN at $59.46 for every dollar of expected revenue over the next 12 months.

VTGN Valuation